Monday 30 November 2015

Indian drugmaker Biocon eyes $1bn revenue in 4 years

India's biggest biotech firm Biocon expects revenue to double to $1 billion in four years as it expands in Europe and the US with new products, its chairperson and managing director said on Saturday. In a tie-up with US generi


Final trial confirms Sanofi's dengue vaccine success

French drugmaker Sanofi, developing the first vaccine against dengue fever, said its product reduced disease cases by 60.8 per cent in a large final clinical trial. Sanofi has invested more than 1.3 billion euros ($1.7 billion) in


Sanofi strong in emerging markets as rivals flag

French drugmaker Sanofi posted better-than-expected quarterly results, bolstered by strong emerging markets, breaking with a trend of earnings misses by European rivals AstraZeneca and GlaxoSmithkline. Sanofi performed strongly in Chi


Novartis announces massive US jobs cuts

Novartis AG is slashing nearly 2,000 jobs in the US ahead of the patent loss of its top-selling blood pressure drug Diovan, the Swiss drugmaker said on Friday, just months after it said would scale back operations in Switzerland. The group

 1 2 3 4 5 >  Last ›

calendarCalendar of Events